The Association Between Azathioprine Genetic Polymorphisms, Clinical Efficacy and Adverse Drug Reactions Among Egyptian Patients with Autoimmune Diseases

被引:1
作者
Abuelsoud, Nermeen [1 ,2 ]
Fayed, Hala [3 ]
Elkateeb, Engy [4 ]
机构
[1] British Univ Egypt, Fac Pharm, Dept Clin Pharm Practice, Cairo, Egypt
[2] Egyptian Russian Univ, Fac Pharm, Dept Pharm Practice Clin Pharm, Cairo, Egypt
[3] Cairo Univ, Kasr Alaini Univ Hosp, Fac Med, Dept Rheumatol & Rehabil, Cairo, Egypt
[4] Cairo Univ, Kasr Alaini Univ Hosp, Fac Med, Dept Chem & Clin Pathol, Cairo, Egypt
关键词
azathioprine; genetic polymorphisms; autoimmune diseases; Egyptian patients; THIOPURINE METHYLTRANSFERASE GENOTYPE; IMPLEMENTATION CONSORTIUM GUIDELINES; CROHNS-DISEASE; ALLELES; TPMT; PHARMACOGENETICS; MERCAPTOPURINE; INHERITANCE; PHARMACOLOGY; FREQUENCIES;
D O I
10.2147/PGPM.S285033
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: The study aimed to detect the frequencies of allelic variants (TPMT*3A, TPMT*3C, and TPMT*3G) in the TPMT genes in the Egyptian population and assess the association between TPMT polymorphisms and azathioprine (AZA)-clinical efficacy and adverse drug reactions among Egyptian patients with autoimmune diseases. Design: A prospective, observational single-center clinical trial. Setting: Rheumatology and Rehabilitation Department, Kasr Alainy University Hospital, Faculty of Medicine, Cairo University. Patients: Patients attending Kasr Alainy Rheumatology Outpatient Clinic between December 1, 2017 and June 30, 2019 were included in the study after signing a consent form. TPMT genetic polymorphisms were detected for all patients, and the association between polymorphisms presence and azathioprine's clinical efficacy and adverse drug reactions were determined. Results: A total of 150 patients with a mean age of 35.85 years were enrolled in this study. About 72% of patients were heterozygous in the TPMT*3 G460A and TPMT*3 A719G mutant alleles and 81% were wild type in the TPMT*2 G238C mutant allele. Abnormal liver function tests were detected in 42% of patients. Myelosuppression was presented as anemia which was detected in 63% of patients, leucopenia in 51%, and thrombocytopenia in 25% of patients. AZA clinical failure has occurred in 50% of patients where AZA was discontinued or shifted to another drug which occurred in 45% of patients. Myelosuppression rates were higher in homozygous patients in the three mutant alleles, but statistically significant in TPMT*2 G238C while not statistically significant in TPMT*3 G460A and TPMT*3 A719G. Females had a higher risk of immunosuppression than males (p-value 0.031). Conclusion: The study provided an overview of the genomic variations in the Egyptian population. Routine TPMT genotyping prior to the initiation of AZA therapy should be considered.
引用
收藏
页码:179 / 187
页数:9
相关论文
共 34 条
  • [31] Pharmacogenetics in rheumatology: the prospects and limitations of an emerging field
    Siva, C
    Yokoyama, WM
    McLeod, HL
    [J]. RHEUMATOLOGY, 2002, 41 (11) : 1273 - 1279
  • [32] Genetic Polymorphism of Inosine Triphosphate Pyrophosphatase Is a Determinant of Mercaptopurine Metabolism and Toxicity During Treatment for Acute Lymphoblastic Leukemia
    Stocco, G.
    Cheok, M. H.
    Crews, K. R.
    Dervieux, T.
    French, D.
    Pei, D.
    Yang, W.
    Cheng, C.
    Pui, C-H
    Relling, M. V.
    Evans, W. E.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (02) : 164 - 172
  • [33] Genomic medicine - Inheritance and drug response.
    Weinshilboum, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (06) : 529 - 537
  • [34] WEINSHILBOUM RM, 1980, AM J HUM GENET, V32, P651